Below are the most recent publications written about "Drug Resistance, Viral" by people in Profiles.
-
Zhang Y, Zmasek C, Sun G, Larsen CN, Scheuermann RH. Hepatitis C Virus Database and Bioinformatics Analysis Tools in the Virus Pathogen Resource (ViPR). Methods Mol Biol. 2019; 1911:47-69.
-
Hassibi A, Manickam A, Singh R, Bolouki S, Sinha R, Jirage KB, McDermott MW, Hassibi B, Vikalo H, Mazarei G, Pei L, Bousse L, Miller M, Heshami M, Savage MP, Taylor MT, Gamini N, Wood N, Mantina P, Grogan P, Kuimelis P, Savalia P, Conradson S, Li Y, Meyer RB, Ku E, Ebert J, Pinsky BA, Dolganov G, Van T, Johnson KA, Naraghi-Arani P, Kuimelis RG, Schoolnik G. Multiplexed identification, quantification and genotyping of infectious agents using a semiconductor biochip. Nat Biotechnol. 2018 09; 36(8):738-745.
-
Hodder S, Squires K, Kityo C, Hagins D, Avihingsanon A, Kido A, Jiang S, Kulkarni R, Cheng A, Cao H. Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women. J Acquir Immune Defic Syndr. 2018 06 01; 78(2):209-213.
-
Yamani LN, Yano Y, Utsumi T, Wasityastuti W, Rinonce HT, Widasari DI, Lusida MI, Hayashi Y. Profile of Mutations in the Reverse Transcriptase and Overlapping Surface Genes of Hepatitis B Virus (HBV) in Treatment-Naïve Indonesian HBV Carriers. Jpn J Infect Dis. 2017 Nov 22; 70(6):647-655.
-
Mo H, Hedskog C, Lawitz E, Brainard DM, Yang J, Delaney W, Worth A, Miller MD. Antiviral response and resistance analysis of treatment-na?ve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256. Antiviral Res. 2017 04; 140:151-157.
-
Yang H, Yang C, Wang Y, Rhodes G, Robinson M, Cheng G, Qi X, Mo H, Tian Y, Pakdaman R, Sheng XC, Kim CU, Delaney WE. Preclinical characterization of the novel HCV NS3 protease inhibitor GS-9256. Antivir Ther. 2017; 22(5):413-420.
-
Wasityastuti W, Yano Y, Widasari DI, Yamani LN, Ratnasari N, Heriyanto DS, Okada R, Tanahashi T, Murakami Y, Azuma T, Hayashi Y. Different Variants in Reverse Transcriptase Domain Determined by Ultra-deep Sequencing in Treatment-na?ve and Treated Indonesian Patients Infected with Hepatitis B Virus. Kobe J Med Sci. 2016 Jun 16; 62(1):E1-8.
-
Cheng G, Tian Y, Doehle B, Peng B, Corsa A, Lee YJ, Gong R, Yu M, Han B, Xu S, Dvory-Sobol H, Perron M, Xu Y, Mo H, Pagratis N, Link JO, Delaney W. In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir. Antimicrob Agents Chemother. 2016 Jan 11; 60(3):1847-1853.
-
Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, Teperman L, Fontana R, Schiff E, Fried M, Doehle B, An D, McNally J, Osinusi A, Brainard DM, McHutchison JG, Brown RS, Charlton M. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015 Dec 31; 373(27):2618-28.
-
Widasari DI, Yano Y, Heriyanto DS, Utsumi T, Yamani LN, Rinonce HT, Wasityastuti W, Lusida MI, Okada R, Murakami Y, Tanahashi T, Azuma T, Hayashi Y. A deep-sequencing method detects drug-resistant mutations in the hepatitis B virus in Indonesians. Intervirology. 2014; 57(6):384-92.